Nearly half of lymphoma patients alive after Gilead's CAR-T ...

Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.

Sanofi snaps up Synthorx for $2.5bn, eyeing cancer immunothe...

Sanofi has agreed to buy cancer drugs firm Synthorx for around $2.5 billion, aiming to strengthen its immune-oncology drug pipeline and creating the possibility of new combination therapies

Early data from Roche's NHL drug mosunetuzumab steals the sh...

There’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising early data from Roche’s mosunetuzumab proved to be one of the major ta

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

App helps cancer patients manage their meds

A healthcare app due to launch at the end of this year aims to empower cancer patients and improve survival outcomes by allowing patients to better manage their medications and care.

Roche steps up Merck challenge with first-line NSCLC approva...